Coherus BioSciences Inc (Coherus) is a commercial-stage biopharmaceutical company that focuses on research, development and commercialization of innovative immunotherapies to treat cancer. Its pipeline products include LOQTORZI (toripalimab-tpzi), a novel PD-1 inhibitor, that treats Nasopharyngeal Carcinoma; Casdozokitug is an investigational recombinant human IgG1 monoclonal antibody for Hepatocellular Carcinoma and Non-Small Cell Lung Cancer; CHS-114 and CHS-1000, which targets Solid Tumors. The company also develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor and YUSIMRY, a biosimilar to Humiram which treats inflammatory diseasesCoherus is headquartered in Redwood City, California, the US.
Coherus BioSciences Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Pipeline | UDENYCA |
toripalimab-tpzi: Nasopharyngeal Carcinoma | YUSIMRY |
CHS-006: Hepatocellular Carcinoma and Non-Small Cell Lung Cancer | CIMERLI |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In February, the company and Pharmakon Advisors entered into an agreement to modify the terms of its loan agreement. |
2024 | New Products/Services | In February, the company introduced UDENYCA ONBODY. |
2024 | Contracts/Agreements | In January, the company entered into an agreement to sell CIMERLI (ranibizumab-eqrn) to Sandoz for US$170 million. |
Competitor Comparison
Key Parameters | Coherus BioSciences Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
---|---|---|---|---|---|
Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
City | Redwood City | Basel | Kenilworth | New York | North Chicago |
State/Province | California | - | New Jersey | New York | Illinois |
No. of Employees | 306 | 103,605 | 72,000 | 88,000 | 50,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Dennis M. Lanfear | President; Chairman; Chief Executive Officer | Executive Board | 2010 | 68 |
Rosh Dias, MD. | Chief Medical Officer | Senior Management | 2022 | - |
Vladimir Vexler, Ph.D. | Chief Scientific Officer | Senior Management | 2018 | 64 |
Scott Saywell | Executive Vice President - Corporate Development | Senior Management | 2023 | - |
Theresa LaVallee, Ph.D. | Chief Development Officer | Senior Management | 2021 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer